Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3230 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Jennifer Lynn Ford und 8 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, LLC, Spring House, Pennsylvania, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors, Retina. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Adeno‐associated virus (AAV) vector‐based gene therapy is an innovative modality being increasingly investigated to treat diseases by modifying or replacing defective genes or expressing therapeutic entities. With its unique anatomic and physiological characteristics, the eye constitutes a very attractive target for gene therapy. Specifically, the ocular space is easily accessible and is generally considered “immune‐privileged” with a low risk of systemic side effects following local drug administration. As retina cells have limited cellular turnover, a one‐time gene delivery has the potential to provide long‐term transgene expression. Despite the initial success with voretigene neparvovec (Luxturna), the first approved retina gene therapy, there are still challenges to be overcome for successful clinical development of these products and scientific questions to be answered. The current review paper aims to integrate published experience learned thus far for AAV‐based retina gene therapy related to preclinical to clinical translation; first‐in‐human dose selection; relevant bioanalytical assays and strategies; clinical development considerations including trial design, biodistribution and vector shedding, immunogenicity, transgene expression, and pediatric populations; opportunities for model‐informed drug development; and regulatory perspectives. The information presented herein is intended to serve as a guide to inform the clinical development strategy for retina gene therapy with a focus on clinical pharmacology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
ORCID-Profile: Jennifer Lynn Ford, Eleni Karatza, Sana Khajeh Pour, Tong-Yuan Yang, Michael Swanson
Zitieren
APA
Ford, J. L., Karatza, E., Mody, H., Nagaraja Shastri, P., Khajeh Pour, S., Yang, T. Y., Swanson, M., Chao, D., & Devineni, D. (2024). Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3230
Vancouver
Ford JL, Karatza E, Mody H, Nagaraja Shastri P, Khajeh Pour S, Yang TY, et al. Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3230
BibTeX
@article{Ford2024,
author = {Ford, Jennifer Lynn and Karatza, Eleni and Mody, Hardik and Nagaraja Shastri, Prathap and Khajeh Pour, Sana and Yang, Tong-Yuan and Swanson, Michael and Chao, Daniel and Devineni, Damayanthi},
title = {Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3230}
}
EUVIMED